Fresenius Medical Care
Fresenius Medical Care (FME) offers services & products in more than 120 countries and cares for more than 310,000 patients in our global network of more than 3,600 dialysis clinics. At the same time, we operate 37 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables.
Offering a variety of therapies, Fresenius Medical Care provides efficient treatment of acute kidney injury to fit each patient's specific needs. Besides the several options for CRRT, Fresenius Medical Care also provides options for plasmapheresis and therapeutic apheresis.
Therapeutic apheresis is a therapy for removing pathogenic substances from blood using filters and adsorbers. With a portfolio of different adsorbers and long-standing expertise in extracorporeal procedures, Fresenius Medical Care delivers a combination of quality and flexible treatment alternatives, designed to treat a wide range of diseases and increase the patient’s quality of life.
In January 2017, Fresenius Medical Care acquired the Xenios company. Xenios offers minimally invasive disposable lung and heart therapies on one single platform. This acquisition is an opportunity to expand FME’s position as the global leader in extracorporeal organ support.
This partner supported the following IFAD meetings:
- IFAD 2012
- IFAD 2017